Active Ingredient(s):Ocrelizumab FDA Approved: * March 28, 2017 Pharm Company: *GENENTECH INC Category:Immunosuppressive
Ocrelizumab, sold under the brand name Ocrevus, is a pharmaceutical drug for the treatment of multiple sclerosis (MS). It is a humanized anti-CD20 monoclonal antibody. It targets CD20 marker on B lymphocytes and hence is an immunosuppressive drug. Ocrelizumab binds to an epitope that overlaps with the epitope to which rituximab binds.
It was approved by the U.S. Food and Drug Administration (FDA) in March 2017, and th...
* May have multiple approval dates, manufacturers, or labelers. 3 Discussions